BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Real-World Use of Nivolumab for the Treatment of Patients With Metastatic Upper Gastrointestinal Cancer in Canada

Completed

Conditions: Upper Gastrointestinal Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 700

Registration Number: NCT06361576

Locations: 🇨🇦
Bayshore Specialty Rx Ltd., Mississauga, Ontario, Canada

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

Recruiting

Conditions: Chronic Lymphocytic Leukaemia
Multiple Myeloma
Non-Hodgkin Lymphoma

Interventions: Biological: Lisocabtagene maraleucel
Biological: Idecabtagene vicleucel

First Posted Date: 2024-04-10

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT06357754

Locations: 🇺🇸
University Of Wisconsin, Madison, Wisconsin, United States
🇩🇪
Universitaetsklinikum Essen (AoR), Essen, Germany
🇯🇵
Kumamoto University, Kumamoto-city, Kumamoto, Japan

and more 1 locations

A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment

Phase 1

Recruiting

Conditions: Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Repotrectinib

First Posted Date: 2024-04-08

Last Posted Date: 2024-07-11

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT06352528

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Local Institution - 0005, Orlando, Florida, United States
🇺🇸
Local Institution - 0006, Miami Lakes, Florida, United States

and more 3 locations

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Active, not recruiting

Conditions: Advanced Renal Cell Carcinoma (aRCC)

Interventions: Combination Product: Pembrolizumab + Lenvatinib combination therapy
Combination Product: Nivolumab + Ipilimumab combination therapy

First Posted Date: 2024-04-03

Last Posted Date: 2024-08-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 327

Registration Number: NCT06345183

Locations: 🇺🇸
Cardinal Health, Dublin, Ohio, United States

Real-World Effectiveness of Mavacamten in Canada

Not yet recruiting

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions: Drug: Mavacamten

First Posted Date: 2024-03-29

Last Posted Date: 2024-03-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 100

Registration Number: NCT06338202

Locations: 🇨🇦
London Health Science Centre (LHSC), London, Ontario, Canada

Real-World Practice Patterns and Outcomes of Lower-Risk Myelodysplastic Syndrome Patients in Japan

Active, not recruiting

Conditions: Lower-risk Myelodysplastic Syndromes

Interventions: Procedure: Red blood cell transfusion

First Posted Date: 2024-03-07

Last Posted Date: 2024-03-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT06298643

Locations: 🇯🇵
Mebix, Inc, Tokyo, Minato-ku, Japan

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

Phase 2

Recruiting

Conditions: Alzheimer Disease, Early Onset

Interventions: Other: Placebo
Drug: BMS-986446

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 475

Registration Number: NCT06268886

Locations: 🇺🇸
Associated Neurologists, P.C. - Danbury Office, Danbury, Connecticut, United States
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇧🇪
UZ Leuven, Leuven, Belgium

and more 196 locations

Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea

Recruiting

Conditions: Moderate-to-severe Plaque Psoriasis

Interventions: Drug: Deucravacitinib

First Posted Date: 2024-02-14

Last Posted Date: 2024-11-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 505

Registration Number: NCT06258668

Locations: 🇰🇷
Local Institution - 0001, Seoul, Korea, Republic of
🇰🇷
Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Phase 3

Recruiting

Conditions: Cardiomyopathy, Hypertrophic

Interventions: Drug: Placebo
Drug: Mavacamten

First Posted Date: 2024-02-12

Last Posted Date: 2024-12-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT06253221

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States
🇮🇹
Istituto Giannina Gaslini, Genova, GE, Italy
🇫🇷
CHU Hopitaux de Bordeaux - Hopital Haut-Leveque, Pessac, France

and more 52 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Phase 1

Recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: BMS-986326
Other: Placebo

First Posted Date: 2024-02-08

Last Posted Date: 2024-07-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT06248814

Locations: 🇨🇿
Pratia Pardubice a.s., Pardubice, Czechia
🇵🇱
Uniwersytecki Szpital Kliniczny im. Fryderyka Chopina w Rzeszowie, Rzeszow, Podkarpackie, Poland
🇨🇿
Clintrial s.r.o., Praha, PR, Czechia

and more 9 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy